Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

• Published in: Blood Vol. 124; no. 8; pp. 1372 - 1377
• Main Authors: Cutler, Corey, Logan, Brent, Nakamura, Ryotaro, Johnston, Laura, Choi, Sung, Porter, David, Hogan, William J., Pasquini, Marcelo, MacMillan, Margaret L., Hsu, Jack W., Waller, Edmund K., Grupp, Stephan, McCarthy, Philip, Wu, Juan, Hu, Zhen-Huan, Carter, Shelly L., Horowitz, Mary M., Antin, Joseph H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 21.08.2014; American Society of Hematology
• Subjects: Adolescent; Adult; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease - mortality; Graft vs Host Disease - prevention & control; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents - administration & dosage; Male; Methotrexate - administration & dosage; Middle Aged; Sirolimus - administration & dosage; Stomatitis - mortality; Stomatitis - prevention & control; Survival Rate; Tacrolimus - administration & dosage; Time Factors; Transplantation

Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approximately 35% of matched, related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) recipients. We sought to determine if the combination of tacrolimus and sirolimus (Tac/Sir) was more effective than tacrolimus and methotr...